NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRA-A (vidarabine) is an antiviral nucleoside analog administered by injection for treatment of viral infections, particularly herpes simplex virus encephalitis and varicella zoster virus infections. It works by inhibiting viral DNA polymerase, preventing viral replication in infected cells. The drug represents an older generation antiviral with limited modern clinical use.
LOE Approaching
Product in late-stage lifecycle with minimal commercial infrastructure; limited team expansion likely.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir
26 enrolled
Herpes SimplexHIV Infections
Career Relevance
VIRA-A offers limited career advancement opportunity; roles are primarily defensive and focused on maintaining compliance and managing declining sales. Working on this product signals involvement in legacy portfolio management rather than growth or innovation initiatives.
Product Manager (legacy portfolio)
Worked on VIRA-A at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.